REC-617 An investigational reversible CDK7 inhibitor in Phase 1/2 development for advanced solid tumors.
Visit productCosigns Received
Be the first Cosign
Put your name behind REC-617.
Add it to your Products I use list and share why you use it.
REC-617 An investigational reversible CDK7 inhibitor in Phase 1/2 development for advanced solid tumors.
Visit productBe the first Cosign
Add it to your Products I use list and share why you use it.